https://www.europapress.es Europa Press https://s01.europapress.net/imagenes/estaticos/eplogo.gif https://www.europapress.es es-ES (C) 2026 Europa Press. Mon, 26 Oct 2026 22:44:18 GMT 60 https://www.europapress.es/comunicados/salud-0910/noticia-comunicado-grunenthal-partners-with-dksh-to-bring-four-important-pain-medicines-to-eight-new-markets-in-asia-pacific-20260928101403.html (Información remitida por la empresa firmante) (Ampliación) .- NEWS AKTUELL About Palexia Palexia (tapentadol) is indicated as a prolonged-release tablet for the management of severe chronic pain in adults which can be adequately managed only with opioid analgesics, and for the management of severe chronic pain in children above 6 years and adolescents, which can be adequately managed only with opioid analgesics. https://www.europapress.es/comunicados/salud-0910/noticia-comunicado-grunenthal-partners-with-dksh-to-bring-four-important-pain-medicines-to-eight-new-markets-in-asia-pacific-20260928101403.html Mon, 28 Sep 2026 08:14:03 GMT Comunicados Comunicados Salud https://www.europapress.es/comunicados/salud-0910/noticia-comunicado-grunenthal-strengthens-its-genetic-medicine-capabilities-and-joins-the-cluster-for-nucleic-acid-therapeutics-20260716104909.html (Información remitida por la empresa firmante) - Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich NEWS AKTUELL // Aachen, Germany, 16 July 2026 – Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients. https://www.europapress.es/comunicados/salud-0910/noticia-comunicado-grunenthal-strengthens-its-genetic-medicine-capabilities-and-joins-the-cluster-for-nucleic-acid-therapeutics-20260716104909.html Thu, 16 Jul 2026 08:49:09 GMT Comunicados Comunicados Salud https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-grunenthal-takes-full-ownership-of-grunenthal-med-20260302104224.html (Información remitida por la empresa firmante) Grünenthal acquired Kyowa Kirin International’s 49% stake in ‘Grünenthal Meds’, a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-grunenthal-takes-full-ownership-of-grunenthal-med-20260302104224.html Mon, 02 Mar 2026 09:42:24 GMT Comunicados Comunicados Internacional https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-grunenthals-proprietary-nav-18-inhibitor-enters-clinical-development-20260218105350.html (Información remitida por la empresa firmante) Aachen, Germany, 18 February 2026 (News Aktuell)– Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-grunenthals-proprietary-nav-18-inhibitor-enters-clinical-development-20260218105350.html Wed, 18 Feb 2026 09:53:50 GMT Comunicados Comunicados Internacional https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-grunenthal-licenses-exclusive-canadian-rights-to-testosterone-replacement-therapy-nebido-to-apotex-20260205154719.html (Información remitida por la empresa firmante) Aachen, Germany & Toronto, Canada, February 5, 2026 (News Aktuell) – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-grunenthal-licenses-exclusive-canadian-rights-to-testosterone-replacement-therapy-nebido-to-apotex-20260205154719.html Thu, 05 Feb 2026 14:47:19 GMT Comunicados Comunicados Internacional